Posted by Michael Wonder on 15 Aug 2019
UnitedHealthcare will prefer Amgen's anti-cancer biosimilars beginning in October
15 August 2019 - In its August 2019 network bulletin, UnitedHealthcare indicated that, beginning 1 October 2019, biosimilar bevacizumab (Mvasi) and biosimilar trastuzumab (Kanjinti), both made by Amgen, will be preferred products for commercial, community, and Medicare Advantage plans.
The reference bevacizumab (Avastin) and trastuzumab (Herceptin) will no longer be preferred products.
Additionally, other biosimilars, not yet launched in the United States, will not be preferred oncology products. In documents related to community plans, UnitedHealthcare indicated that Pfizer’s bevacizumab biosimilar (Zirabev), and trastuzumab biosimilars made by Celltrion and Teva (Herzuma), Mylan and Biocon (Ogivri), Samsung Bioepis (Ontruzant), and Pfizer (Trazimera) will be non-preferred products.
